Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.78 |
| ▸ | DRD1 | P21728 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | PDE4A | P27815 | 1/20 | 0.78 |
| ▸ | TSLP | Q969D9 | 13/20 | 0.39 |
| ▸ | SHH | Q15465 | 1/20 | 0.38 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24478636 | 0.97 | CTSL (0.79) | CTSLDRD1PTGS1PDE4ATSLP | |
| SCHEMBL14446086 | 0.95 | CTSL (0.76) | CTSLDRD1PTGS1PDE4ATSLP | |
| SCHEMBL8227154 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8420524 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8221832 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8415773 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL10157516 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL8422213 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL21250583 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH | |
| SCHEMBL14446856 | 0.94 | CTSL (0.88) | CTSLDRD1PTGS1PDE4ASHH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | TAMBO, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20220259254-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | TAMBO, INC. | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259254-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | TIE1, CD74, MERTK | CTSL 1859/4885DRD1 4067/4885PTGS1 1094/4885 |
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | ICOS, CD74, PBK | CTSL 1828/4885DRD1 4039/4885PTGS1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.